| 000 | 01941nam a2200469 i 4500 | ||
|---|---|---|---|
| 999 |
_c282301 _d282301 |
||
| 001 | on1100067197 | ||
| 003 | OCoLC | ||
| 005 | 20190703095857.0 | ||
| 006 | m o d f | ||
| 007 | cr bn||||a|||| | ||
| 008 | 190506s2019 dcu ob f000 0 eng c | ||
| 040 |
_aPUCPR _beng _erda _epn _cGPO _dGPO _dMvI |
||
| 042 | _apcc | ||
| 043 | _an-us--- | ||
| 074 | _a1008-I (online) | ||
| 086 | 0 | _aY 1.1/8:116-47 | |
| 099 | _aY 1.1/8:116-47 | ||
| 110 | 1 |
_aUnited States. _bCongress. _bHouse. _bCommittee on Energy and Commerce, |
|
| 245 | 1 | 0 |
_aOrange Book Transparency Act of 2019 : _breport (to accompany H.R. 1503) (including cost estimate of the Congressional Budget Office). |
| 264 | 1 |
_a[Washington, D.C.] : _b[U.S. Government Publishing Office], _c[2019] |
|
| 300 | _a1 online resource (62 pages). | ||
| 336 | _btxt | ||
| 337 |
_bc _2rdamedia |
||
| 338 |
_bcr _2rdacarrier |
||
| 490 | 1 |
_aReport / 116th Congress, 1st session, House of Representatives ; _v116-47 |
|
| 500 | _a"May 2, 2019." | ||
| 500 | _aCRDP Program record. | ||
| 504 | _aIncludes bibliographical references. | ||
| 588 | _aDescription based on online resource, PDF version; title from caption (govinfo, viewed May 6, 2019). | ||
| 776 | 0 | 8 |
_aUnited States. Congress. House. Committee on Energy and Commerce. _tOrange Book Transparency Act of 2019 _w(OCoLC)1100767854 |
| 810 | 1 |
_aUnited States. _bCongress. _bHouse. _tReport ; _v116-47. |
|
| 856 | 4 | 0 | _uhttps://purl.fdlp.gov/GPO/gpo119882 |
| 050 | 4 |
_aKF32 _b.E55 2019a |
|
| 650 | 0 |
_aPharmaceutical industry _zUnited States. |
|
| 650 | 0 |
_aDrugs _zUnited States _xCosts. |
|
| 650 | 0 |
_aPrescription pricing _xLaw and legislation _zUnited States. |
|
| 650 | 0 |
_aDrugs _zUnited States _xGeneric substitution. |
|
| 650 | 0 |
_aGeneric drugs _zUnited States _xCosts. |
|
| 650 | 0 |
_aCompetition _zUnited States. |
|
| 655 | 7 |
_aLegislative materials. _2lcgft |
|
| 942 |
_2sudocs _c8 |
||